- RecruitingTherapeutic exploratory (Phase II)
CDX0159-07: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria
This study is testing a new medicine called Barzolvolimab for people with chronic inducible urticaria (hives that can be triggered). It aims to see if the medicine can stop hives from appearing when triggered by cold or scratching, and if it's safe to use.
For: Chronic Inducible UrticariaPoland · Bulgaria · Latvia - Enrolling by invitationPHASE3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
This study looks at the long-term effects and safety of a drug called barzolvolimab for chronic hives (CSU). It's for adults who have already completed earlier studies with this drug, aiming to see how well it works over a longer time and to give ongoing access to treatment if needed.
For: Chronic Spontaneous UrticariaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
This study is testing a new medicine, barzolvolimab, for people with chronic spontaneous urticaria (CSU), also known as chronic hives. It aims to see if the medicine is safe and helps reduce hives better than a dummy medicine (placebo) for those whose current treatments aren't enough.
For: Chronic Spontaneous UrticariaUnited States · Australia · Bulgaria - Active not recruitingPHASE3
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
This study looks at a new medicine called barzolvolimab for chronic hives that don't respond well to usual treatments. It will check if the medicine works, if it's safe, and how well people tolerate it compared to a dummy medicine.
For: Chronic Spontaneous UrticariaUnited States · Argentina · Belgium - RecruitingPHASE3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
This study looks at a new drug, barzolvolimab, for people with cold urticaria or symptomatic dermographism – skin conditions causing hives or itching from cold or scratching. It checks if the drug is safe and helps when usual antihistamines don't work.
For: Chronic Inducible Urticaria · Cold Urticaria · Cold-Induced UrticariaUnited States · Germany · Lithuania